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Abstract
Background
Epilepsy and progressively worsening severe chronic headaches (WSCH) are the two most
common clinical manifestations of neurocysticercosis, a form of cysticercosis. Most commu-
nity-based studies in sub-Saharan Africa (SSA) use a two-step approach (questionnaire
and confirmation) to estimate the prevalence of these neurological disorders and neurocysti-
cercosis. Few validate the questionnaire in the field or account for the imperfect nature of
the screening questionnaire and the fact that only those who screen positive have the oppor-
tunity to be confirmed. This study aims to obtain community-based validity estimates of a
screening questionnaire, and to assess the impact of verification bias and misclassification
error on prevalence estimates of epilepsy and WSCH.
Methodology/Principal findings
Baseline screening questionnaire followed by neurological examination data from a cluster
randomized controlled trial collected between February 2011 and January 2012 were used.
Bayesian latent-class models were applied to obtain verification bias adjusted validity esti-
mates for the screening questionnaire. These models were also used to compare the
adjusted prevalence estimates of epilepsy and WSCH to those directly obtained from the
data (i.e. unadjusted prevalence estimates). Different priors were used and their corre-
sponding posterior inference was compared for both WSCH and epilepsy. Screening data
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were available for 4768 individuals. For epilepsy, posterior estimates for the sensitivity var-
ied with the priors used but remained robust for the specificity, with the highest estimates at
66.1% (95%BCI: 56.4%;75.3%) for sensitivity and 88.9% (88.0%;89.8%) for specificity. For
WSCH, the sensitivity and specificity estimates remained robust, with the highest at 59.6%
(49.7%;69.1%) and 88.6% (87.6%;89.6%), respectively. The unadjusted prevalence esti-
mates were consistently lower than the adjusted prevalence estimates for both epilepsy and
WSCH.
Conclusions/Significance
This study demonstrates that in some settings, the prevalence of epilepsy and WSCH can
be considerably underestimated when using the two-step approach. We provide an analytic
solution to obtain more valid prevalence estimates of these neurological disorders, although
more community-based validity studies are needed to reduce the uncertainty of the esti-
mates. Valid estimates of these two neurological disorders are essential to obtain accurate
burden values for neglected tropical diseases such as neurocysticercosis that manifest as
epilepsy or WSCH.
Trial registration
ClinicalTrials.gov NCT03095339.
Author summary
Epilepsy and progressively worsening severe chronic headaches are the two most common
clinical manifestations of neurocysticercosis, a form of cysticercosis. To understand where
the prevalence of these neurological disorders is highest for targeted infection control,
valid prevalence estimates are needed. Most neuroepidemiological studies conducted in
low-resource settings use a two-step approach to identify cases (screening questionnaire
followed by physician examination among screened positives) to obtain prevalence and
burden estimates. We found that this most commonly-used two-step approach in com-
munity-based studies leads to an underestimation of the prevalence in our study. Our
paper provides an analytic solution to reduce errors in estimating the prevalence of neuro-
logical disorders in community-based studies when using the two-step approach. Our
proposed approach provides more valid estimates of the prevalence of these neurological
disorders and could be used to better reflect the consequences that neglected tropical dis-
eases manifesting as epilepsy or headaches have on people’s health and disabilities.
Introduction
The Global Burden of Disease Study estimates epilepsy and migraines to be among the 30 lead-
ing causes of years of life lost due to disability [1]. The prevalence of epilepsy and headaches
varies globally, likely due to different risk factors across populations or epidemiological biases
[2,3]. A meta-analysis estimated the median prevalence of lifetime epilepsy in developing
countries at 15.4‰ in rural and 10.3‰ in urban areas, higher than the estimated 5.8‰ in
developed countries [4]. The estimated prevalence of lifetime epilepsy shows substantial varia-
tion within sub-Saharan Africa (SSA) [4–8], ranging from 7.3‰ to 29.5‰. In contrast, the
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prevalence of migraine in adults is reported to be higher in developed countries than that in
developing countries, with an estimate of 15% in Europe and 5% in Africa [3]. The limited
data collected on headaches in SSA suggest that the one-year period prevalence ranges from
3.0% to 5.4% for migraines, and 1.7% to 7.0% for tension-type headaches [9–11]. Reasons for
the opposite trends in the frequency of epilepsy and headaches may be due to the distribution
of socio-economical, cultural, and infectious risk factors and genetic susceptibilities, as well as
important methodological differences between studies [1,3,12]. In particular, whereas preva-
lence data on epilepsy and headaches often originate from national surveys or nation-wide
electronic health records in high income countries, it is not the case in SSA, where data origi-
nate from research projects conducted in a small number of communities. The way these neu-
rological disorders are measured in different settings could result in important
misclassification error bias which, in turn, could explain some of this variation in estimates.
Rural community-based studies in SSA often use a two-step approach to identify neurologi-
cal disorder cases for prevalence estimates [13,14]. In step one, a screening test, often in the
form of a questionnaire, is used to identify positive cases for the neurological disorder(s) of
interest in the study population. The participants in this step can be randomly selected or iden-
tified via door-to-door visits. In step two, a physician or sometimes a neurologist confirms the
given neurological disorder(s) through a medical examination, often only among those
screened positive [15–19]. Diagnosis through electroencephalography is often not possible in
rural community-based settings due to limited resources [13], and therefore, the physician/
neurologist’s diagnostic is often considered as the gold standard.
The two-step approach is frequently used for studies in low-resource settings due to its con-
venience and cost-effectiveness. Despite its frequent use, the prevalence estimates from the
two-step approach can be seriously biased from failure to account for the imperfect validity of
the tests, referred to as misclassification error hereinafter, employed either at step one or step
two, or both. The validity of a test is typically assessed by its sensitivity and specificity, and the
correct sensitivity and specificity must be used to obtain unbiased prevalence estimates. How-
ever, for questionnaires used as the screening tool for epilepsy and headaches, especially those
used in rural areas of SSA, little is known about their validity. In most studies, standardized
screening questionnaires are used, but their validity is not determined in the study population
[8–10,19]. To our knowledge, only two studies have reported validity estimates of epilepsy
screening questionnaires in the general population; however, neither addresses potential verifi-
cation bias in their validity estimates [20,21]. Verification bias occurs when the participants
from step one have different probabilities of being selected for step two [22]. For example,
individuals screened positive at step one have a much higher chance of being confirmed by a
physician or neurologist, compared to those screened negative, who are rarely, if at all, exam-
ined at step two. As a result, the selected individuals at step two are not representative of the
entire study population, which may lead to biased prevalence estimates.
These biases can have important consequences in evaluating the global burden of neglected
tropical diseases. For example, epilepsy and progressively worsening severe chronic headaches
(WSCH) are the most frequently observed clinical signs of neurocysticercosis (NCC), a pre-
ventable infection with the eggs of Taenia solium [23], which is present in communities with
poor sanitation and free roaming pigs [24,25]. Most epidemiological studies evaluating the
prevalence of NCC in communities will first identify people with epilepsy, and rarely with
headaches, and invite them to obtain brain imaging to diagnose NCC. The proportion of NCC
among people with epilepsy (or rarely headaches) is then used to estimate the prevalence of
epilepsy-associated (or headaches-associated) NCC in the study population. Such estimates
may then be combined to the prevalence of epilepsy or headaches in the population to estimate
Disability Adjusted Life Years (DALYs) associated with NCC [26–28]. The global burden of
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disease initiative used this approach to estimate DALYs associated with cysticercosis [29].
Therefore, to obtain accurate estimates of the global burden of NCC, or of any neglected tropi-
cal disease causing neurological signs, we first need valid prevalence estimates of epilepsy and
WSCH. From there, we may obtain more reliable assessments of the relative burden of NCC,
or other neglected tropical diseases manifesting as epilepsy or headaches, compared to other
infections or chronic diseases.
In this paper, we aimed to quantify the bias introduced in the prevalence estimates when
failing to account for the verification bias and the imperfect validity of the screening tool using
data collected from 60 villages in Burkina Faso. We also investigated the validity of screening
questionnaire by estimating the sensitivity and specificity to detect epilepsy and WSCH.
Methods
Study setting and participants
Baseline cross-sectional data collected from February 2011 to January 2012 for a cluster ran-
domized controlled trial were used. The aim of the parent study was to estimate the effective-
ness of a community-based educational intervention to reduce the cumulative incidence of
human and porcine cysticercosis in 60 villages of Burkina Faso [30]. From 70 to 80 individuals
aged 5 years or above were sampled in each village using a cluster random sampling approach
described elsewhere [30].
Ethics
The University of Oklahoma Health Sciences Center Institutional Review Board and the Cen-
tre MURAZ ethical review panel (Burkina Faso) approved this study. The field staff read the
written consent forms to participants and answered all their questions. Consent forms were
signed, marked with a cross or a fingerprint by those who were unable to write. All consent
forms were signed by a witness. Parents of individuals 5 to 16 years of age gave consent for
their children. Individuals aged 10 to 15 years were invited to give their assent. All participants
were given a bar of soap as incentive. The parent study was registered through clinicaltrials.
gov (NCT03095339).
Screening of epilepsy and severe chronic headaches
In step one of the two-step approach, each participant was screened for epilepsy and WSCH
using a screening questionnaire (S1 Questionnaire). Questions related to epilepsy were based
on the International League Against Epilepsy screening of epilepsy questionnaire developed by
Preux et al.[31], and was previously used in three villages in the same study area [32]. Ques-
tions related to headaches were designed to capture NCC-related headaches [33].
Diagnostic confirmation by physicians/neurologists
In step two, all individuals screened positive for either epilepsy or WSCH from the screening
questionnaire were invited to be examined by a study physician. In addition, 231 screened-
negative individuals were randomly selected to be examined by the physician. The medical
examination results were collected on a medical examination questionnaire (S2 Question-
naire). Two medical examination rounds took place with the second round aimed at capturing
individuals who were absent during the first round and to examine patients from the more
remote province of Nayala. The physicians discussed any uncertain diagnosis with the neurol-
ogist on the phone at the time of the medical examination. At the end of the study, the neurol-
ogist reviewed all diagnoses and his final diagnosis was considered as the gold standard. The
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diagnostic result that confirmed whether the individual had epilepsy and/or WSCH was used
to assess the validity of the screening questionnaire.
Definition of epilepsy and severe chronic headaches
Epilepsy was defined as having more than one seizure of central nervous system origin without
apparent cause [34]. Individuals not meeting the epilepsy case definition were considered as
epilepsy-free (i.e., screened negative for epilepsy). Six individuals diagnosed with single epilep-
tic seizures were excluded from all analyses.
WSCH was defined as having symptoms arising more than weekly for two weeks or more,
with each episode lasting at least 3 hours, and progressively worsening in severity with time.
Headaches had to be severe enough to require analgesic or to prohibit working, playing,
attending school, or partaking in daily activities [35]. Individuals not meeting the WSCH defi-
nition were considered as WSCH-free (i.e., screened negative for WSCH).
Statistical analysis
The statistical analyses aimed at assessing the bias from failing to correct for both verification
bias and misclassification error, when estimating the prevalence of epilepsy and WSCH in the
study population. To assess the degree of the bias, we first calculated the unadjusted estimates,
where no correction was made for verification bias and misclassification error. The unadjusted
estimates were obtained by running a Bayesian binomial model, where the number of con-
firmed cases of either epilepsy or WSCH was assumed to result from a binomial distribution
with a probability corresponding to the unadjusted prevalence and the number of individuals
screened. The prior choice for the prevalence parameter is discussed below.
The adjusted prevalence estimate was obtained by running a Bayesian latent-class model
[22]. In this model, the probabilities that participants were selected for the confirmation test at
step two were specified by a set of conditional distributions. Participants with different selec-
tion probabilities had different conditional probability distributions. This way, the selection
probabilities were correctly accounted for, eliminating verification bias. To obtain the specific-
ity and sensitivity estimates of the screening questionnaire while correcting for verification
bias, we provided prior information on the model parameters of sensitivity and specificity. Dif-
ferent priors, including both informative and non-informative (i.e., vague) priors, were inves-
tigated in modeling either epilepsy or WSCH. Specifically, for epilepsy, one set of informative
priors based on the sensitivity and specificity estimates for similar epilepsy screening question-
naires from two previous community-based studies [25, 26] were used. In these studies, sensi-
tivity and specificity were estimated as 92.9% and 79.3%, and 99.6% and 72.4%, respectively.
To allow some variability, the prior sensitivity and specificity values in our analysis were
assumed to follow beta distributions with mean based on these validity estimates and a stan-
dard deviation of 0.05. This led to a Beta(54.8, 17.5) prior for sensitivity, and a Beta(12.9, 0.5)
for specificity. We also considered the vague priors of Unif(0.5, 1) for both parameters. Since
epilepsy was highly stigmatized in SSA [6] and some forms of partial epilepsy may be difficult
to identify, we also used a vague prior of Unif(0.3, 1) for the sensitivity of epilepsy screening.
Due to the lack of validity studies for WSCH screening, the same informative priors as epilepsy
were adopted for WSCH. We also ran the model with vague priors of Unif(0.5, 1) for both the
specificity and sensitivity, and results were compared with those obtained using informative
priors.
When modeling each epilepsy and WSCH, we used a vague Unif(0, 0.3) for the unadjusted
prevalence estimate. For the adjusted prevalence parameter, a vague prior of N(0, 10) was used
(on logit scale).
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We used WinBUGS [36] for all the Bayesian analyses and reported the posterior mean and
95% credible intervals. The bias was then evaluated by the ratio of the adjusted to the unad-
justed estimates, with the Bayesian credible interval for the ratio excluding 1 indicating the
existence of bias.
Assessing the impact of different screening strategies on the bias
introduced by verification bias and misclassification error
We examined three scenarios reflecting different screening strategies often used in commu-
nity-based studies conducted in low-resource areas. In Scenario 1, we estimated the unad-
justed prevalence using the screening information for only one neurological disorder instead
of for epilepsy and WSCH, to reflect a common situation in the existing literature where only
one neurological disorder was studied at a time instead of both disorders simultaneously. In
Scenario 2, we estimated the unadjusted estimate using the information for participants that
were only examined in the first medical round. This scenario was considered to reflect situa-
tions where there were insufficient personnel and monetary resources to find people absent
from the village during the initial visit. Scenarios 1 and 2 are fairly common in field studies
conducted in resource-poor contexts. In Scenario 3, we only used the screening information
for the unadjusted prevalence estimate, reflecting a situation where the validity of the screen-
ing questionnaire cannot be assessed. We calculated the adjusted estimates resulting from each
scenario, and evaluated the bias estimating the ratio of the verification bias and misclassifica-
tion error-adjusted to the unadjusted estimates.
Assessing the impact of the proposed methods on the frequency estimates
of NCC-associated epilepsy and WSCH
In this exercise, the impact of verification bias and misclassification error on community-
based estimates of NCC-associated epilepsy and WSCH prevalence and number of cases was
evaluated. To obtain the estimated prevalence of NCC-associated epilepsy and WSCH for our
study population, the adjusted and unadjusted estimates of epilepsy and WSCH prevalence
were multiplied by the proportion of NCC among people with epilepsy reported in a meta-
analysis [37] and the proportion of NCC among people with headaches reported in a case-con-
trol study [38]. We then investigated the difference between the adjusted and unadjusted prev-
alence estimates of NCC-associated epilepsy and WSCH. To obtain the difference between the
number of NCC-associated epilepsy and WSCH cases in our study population, the estimated
adjusted and unadjusted prevalence estimates were multiplied by the study population size.
We assumed that the mean number of NCC-associated cases of epilepsy and WSCH would fol-
low beta distributions with parameters based on the estimated means in the published studies
(29% for epilepsy and 4.7% for headaches) [37,38] and a standard deviation of 2.75%. All esti-
mates were run using the set of informative priors described earlier. The adjusted prevalence
and number of cases of NCC-associated epilepsy and WSCH were also estimated under the
three screening strategies described above.
Results
Description of the study population
A total of 4794 individuals were sampled at baseline, including the analytical sample of 4768
with complete screening data. Of these, 669 (14.0%) screened positive for epilepsy (7.1%),
WSCH (2.8%) or both (4.2%) (Table 1). A physician examined 609 (91.0%) screened-positive
and 231 (5.6%) screened-negative individuals. The higher proportion of screened-positive
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examined by a physician compared to those screened-negative showed evidence for the need
to adjust for potential verification bias (Fig 1).
Of those examined in step two, 748, 57 and 35 were seen at the first, second and both medi-
cal rounds, respectively. Perfect agreement was observed for those examined at both rounds.
Table 1 describes the characteristics of the analytical sample, and the screening and medical
examination results. The majority of participants were either a farmer or housewife and a high
proportion did not complete primary school.
Table 2 provides the posterior estimates of the unadjusted prevalence and the correspond-
ing adjusted prevalence with the associated sensitivity and specificity estimates, using the dif-
ferent sets of priors. The epilepsy screening questionnaire showed posterior sensitivity and
specificity estimates of moderate variation with different priors used, while the specificity esti-
mates remained robust. The posterior sensitivity estimate was 44.7% (95%BCI: 33.0%;60.0%)
with the most vague prior and increased to 66.1% (95%BCI: 56.4%,75.3%) with the informative
priors based on previous literature. Posterior sensitivity and specificity estimates of the WSCH
screening questionnaire were less affected by the priors. Despite the variation in the estimated
sensitivity and specificity, the unadjusted prevalence estimates were consistently lower than
Table 1. Characteristics of the 4768 individuals screened for epilepsy and worsening severe chronic headaches
(WSCH) across 60 villages in three provinces of Burkina Faso, 2011–2012.
Characteristic N (%)
Age (24 missing)
6–17 years 1515 (31.9%)
18–40 years 1679 (35.4%)
41 years and older 1550 (32.7%)
Gender (1 missing)
Female 2564 (53.8%)
Male 2203 (46.2%)
Education
Did not complete primary school 4171 (87.5%)
Completed primary school 371 (7.8%)
Completed at least secondary school 226 (4.7%)
Occupation (1 missing)
Student/Pupil 924 (19.4%)
Farmer/gardener 1819 (38.2%)
Housewife/house cleaner 1672 (35.0%)
Commerce/ Salaried/ Skilled self-employed/ Unemployed 352 (7.4%)
Screening results
Negative 4099 (86.0%)
Positive for epilepsy 337 (7.0%)
Positive for WSCH 134 (2.8%)
Positive for epilepsy and WSCH 198 (4.2%)
Diagnosis results from medical exam
None 4460 (93.5%)
Epilepsy 147 (3.1%)
WSCH 142 (3.0%)
Epilepsy and WSCH 19 (0.4%)
Impact of verification bias and misclassification error on the prevalence estimates of epilepsy and WSCH
https://doi.org/10.1371/journal.pntd.0007109.t001
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the adjusted ones for both epilepsy and WSCH, as indicated by the posterior bias distribution
lying under the value of 1. Somewhat less bias was observed using the informative priors.
Bias (i.e., where the unadjusted estimate was smaller than the adjusted estimate) was intro-
duced for both epilepsy and WSCH (Figs 2 and 3) under the two most common screening
strategies found in the literature, namely Scenarios 1 (i.e. when we assumed that the study
would only screen for one neurological disorder) and 2 (i.e. when resources would not allow
for returning to communities to examine those absent during a first visit). The magnitude of
the bias was similar to that observed in the main analyses for epilepsy, but more marked for
WSCH. For Scenario 3 (i.e. when only screening results were used), an important positive bias
was present where the unadjusted prevalence estimate of 11.2% (95%BCI: 10.4%; 12.2%) was
considerably larger than the adjusted prevalence for epilepsy when more informative priors
were used. For WSCH, Scenario 3 resulted in a negligible positive bias. The magnitude of the
bias did not vary extensively by the priors used for epilepsy and WSCH, except for epilepsy in
Scenario 3.
Fig 1. Flowchart of two-step confirmation for epilepsy and progressively worsening severe chronic headaches among 4768 individuals in 60 villages of Burkina
Faso.
https://doi.org/10.1371/journal.pntd.0007109.g001
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Impact of verification bias and misclassification error on the frequency
estimates of NCC-associated epilepsy and WSCH in the base scenario and
under different screening strategies
Using the study data, the differences between the adjusted and unadjusted prevalence and
number of NCC-associated epilepsy were 0.6% (95%BCI: 0.3%; 1.0%) and 29 cases (95%BCI:
13; 49), respectively.
Discussion
This was the first study to estimate the sensitivity and specificity of a screening questionnaire
for epilepsy and WSCH in the community while adjusting for both verification and misclassifi-
cation error bias. This was also the first study to quantify the bias from failing to account for
verification and misclassification error bias when estimating the prevalence of epilepsy and
WSCH in a community-based study.
Our sampling strategy was not designed to provide population prevalence estimates of epi-
lepsy and WSCH in Burkina Faso as a whole, in the three study provinces, or even the villages
selected for the parent study. Indeed, our sampling strategy, which favored concessions with
pigs, was likely to result in higher estimates of prevalences than what would have been
observed if a simple random sampling strategy had been adopted. Nonetheless, we provided
below prevalence estimates from other community-based studies conducted in resource-poor
settings using the two-step approach. In our study sample, the unadjusted prevalence of epi-
lepsy was higher than that of 1.6% (95%CI: 1.2%;2.0%), 1.1% (95%CI: 0.9%; 1.4%) and 0.5%
Table 2. Unadjusted and adjusted prevalence estimates (95% Bayesian Credible Interval (95%BCI)) of lifetime
epilepsy and severe chronic headaches (WSCH) using data from 4768 individuals in Boulkiemde´, Nayala and San-
guie´ provinces, Burkina Faso. The table shows results from different priors used for sensitivity, specificity and preva-
lence as well as posterior estimates of the sensitivity and specificity of the screening questionnaire for epilepsy and
WSCH using these priors. All analyses used the prior of N(0, 10) for the prevalence parameter.
Posterior Estimate (95%BCI) for Epilepsya Posterior Estimate (95%BCI) for WSCHa
Unadjusted prevalence 3.5% (3.0%;4.0%) 3.4% (2.9%;3.9%)
Vague priors set 1: Sensitivity Uniform(0.3,1) and Specificity Uniform(0.5,1)
Adjusted prevalence 7.9% (5.9%;10.6%) Not applicable
Biasb 0.4 (0.3;0.6) Not applicable
Sensitivity 44.7% (33.0%;60.0%) Not applicable
Specificity 88.6% (87.6%;89.6%) Not applicable
Vague prior set 2: Sensitivity Uniform(0.5,1) and Specificity Uniform(0.5,1)
Adjusted prevalence 6.7% (5.4%;8.0%) 6.7% (5.6%;7.9%)
Biasb 0.5 (0.4;0.7) 0.5 (0.4;0.6)
Sensitivity 53.7% (50.2%;64.7%) 51.7% (50.1%;58.1%)
Specificity 88.8% (87.8%;89.7%) 88.4% (87.4%;89.3%)
Informative prior: Sensitivity cBeta(54.8, 17.5) and Specificity dBeta(12.9, 0.5)
Adjusted prevalence 5.6% (4.6%;6.8%) 6.0% (4.9%;7.4%)
Biasb 0.6 (0.5;0.8) 0.6 (0.4;0.7)
Sensitivity 66.1% (56.4%;75.3%) 59.6% (49.7%;69.1%)
Specificity 88.9% (88.0%;89.8%) 88.6% (87.6%;89.6%)
aIncludes 19 individuals with both epilepsy and WSCH
bBias was estimated as follows: Unadjusted prevalence/ Adjusted prevalence
cBeta(54.8, 17.5): mean = 0.759, variance = 0.0025
dBeta(12.9, 0.5): mean = 0. 963, variance = 0.0025
https://doi.org/10.1371/journal.pntd.0007109.t002
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(95%CI: 0.2%;0.8%) found in Benin, Tanzania and Nigeria, respectively [7,15,39]. Our estimate
was also higher than that of 0.6% (95%CI: 0.5%;0.7%) found in Cambodia where a screening
questionnaire similar to ours was used [40]. Similarly, our unadjusted estimate was higher
than the first study conducted in rural Burkina Faso, which estimated an epilepsy prevalence
of 1.1% in 18 villages [41]. Our prevalence estimate was most similar to a recent Burkinabe´
study, conducted by the same research group, which estimated a lifetime epilepsy prevalence
of 4.5% (95%CI: 3.3%;6.0%) in three villages purposely sampled to have a high prevalence of
epilepsy [32]. This supported the suspicion that our study sample might represent people at
higher risk of epilepsy than the general population.
Our unadjusted estimate of lifetime WSCH prevalence was similar to the lifetime migraine
prevalence estimate of 3.3% (95%CI: 2.4%;4.6%) in Benin [42], and lower than the lifetime
migraine prevalence estimate of 5.3% (95%CI: 5.0%; 5.6%) in Nigeria [43]. Lifetime prevalence
estimates of tension-type headaches in SSA were unavailable for comparison. Compared to
published one-year prevalence estimates of tension-type headaches, ours was higher than the
1.7% (95%CI: 1.5%; 1.9%) prevalence in Ethiopia among adults 20 years and older, and lower
than the 7.0% (95%CI: 6.5%;7.6%) prevalence in Tanzania among all ages [9,11]. This sug-
gested that our sampling strategy might have not influenced the estimated frequency of
WSCH as much as it did for epilepsy.
The posterior estimates of the specificity for the neurological screening questionnaire were
similar for epilepsy and WSCH, and were consistently around 88%. These estimates were
slightly lower than those previously reported [20,21], possibly because our study population
had a higher proportion of false negatives compared to the previously published validity
Fig 2. Bias (unadjusted prevalence/adjusted prevalence) observed from estimating epilepsy prevalence under different scenarios among 4768 individuals across
60 villages in three provinces of Burkina Faso, 2011–2012. Blue: Vague prior for sensitivity (Uniform(0.3,1)) and specificity (Uniform(0.5,1)), Red: Vague prior for
sensitivity and specificity (both Uniform(0.5,1) and Green: Informative prior for sensitivity (Beta(54.8,17.5)) and specificity (Beta(12.9,0.5)). Scenario 1: the unadjusted
prevalence estimated using the screening information for only one neurological disorder. Scenario 2: the unadjusted prevalence estimated using only the confirmation
information from the first medical round. Scenario 3: the unadjusted prevalence estimated in the situation where a medical examination was not conducted.
https://doi.org/10.1371/journal.pntd.0007109.g002
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studies. Study participants in our study may also have been less likely to report their symptoms
compared to those in Ecuador and Bolivia, perhaps due to the stigmatizing effects of epilepsy
in SSA [6]. The posterior estimates of sensitivity varied depending on the priors used, particu-
larly for epilepsy. The sensitivity posterior median was higher when prior knowledge [20,21]
information was used and lower for vague priors; although the credible intervals overlapped. A
similar observation where the sensitivity parameter was more affected to the prior choice was
also found in a study assessing the validity measures of a screening test for human papillomavi-
rus [44].
Our sensitivity estimates were lower and specificity estimates higher for epilepsy than that
found in validation studies conducted in clinical settings with estimates of sensitivity between
91% and 100% and specificity between 51% and 85% [19,20,45]. Placencia et al. found lower
sensitivity and similar specificity estimates when the same screening questionnaire was used in
the community as compared to the clinic [20]. Such discrepancies may be due to spectrum
bias where populations in clinical settings have more severe disease and acknowledge their
symptoms more, thereby increasing the test sensitivity. The observed estimates from clinical
settings may also result in part from verification bias, which typically leads to an overestima-
tion of the sensitivity and underestimation of the specificity [22]. Our sensitivity estimates for
Fig 3. Bias (unadjusted prevalence/adjusted prevalence) observed from estimating severe chronic headaches prevalence under different scenarios among
4768 individuals across 60 villages in three provinces of Burkina Faso, 2011–2012. Red: Vague prior for sensitivity and specificity (both Uniform(0.5,1) and
Green: Informative prior for sensitivity (Beta(54.8,17.5)) and specificity (Beta(12.9,0.50)). Scenario 1: the unadjusted prevalence estimated using the screening
information for only one neurological disorder. Scenario 2: the unadjusted prevalence estimated using only the confirmation information from the first medical
round. Scenario 3: the unadjusted prevalence estimated in the situation where a medical examination was not conducted.
https://doi.org/10.1371/journal.pntd.0007109.g003
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epilepsy were similar to the two other community-based studies with sensitivities of 72.4%
(95% CI: 52.8–87.3) and 79.3% [20,21]. To our knowledge, prevalence studies using the two-
step approach for WSCH have not reported validity estimates.
Even in a situation where 90% of those screened positive were examined by a physician, sig-
nificant biases were observed. The unadjusted prevalence estimates were consistently lower
than the adjusted prevalence estimates regardless of the priors used. However, the adjusted
prevalence estimates were highly dependent on priors, particularly for epilepsy, which intro-
duced considerable uncertainty. Such uncertainty could be reduced by conducting more com-
munity studies assessing and reporting validity estimates of screening. The validity estimates
were expected to vary from one community to the next, due to how epilepsy and WSCH were
reported by patients and to the way interviewers were trained to use the questionnaire. This
would also result in varied bias estimates. Therefore, the reported sensitivity and specificity
estimates of the screening questionnaire may not be applicable to other communities.
We chose the Bayesian framework [46,47] to simultaneously correct for verification bias
and misclassification error in the two-step approach for two reasons. First, verification bias
can be treated as a missing data problem, and therefore be corrected in a straightforward man-
ner. Second, verification bias and misclassification error can be addressed simultaneously by
including an additional level in the Bayesian model estimating the specificity and sensitivity of
the invalid test(s). The capture-recapture method is an alternative approach for obtaining cor-
rected prevalence estimates [13]. This method combines multiple sources of information inde-
pendently, such as medical records and non-medical interviews with community members,
with the two-step approach. This method yielded higher prevalence estimates than the two-
step approach alone in two studies in Benin [7,42]. Our bias estimation method using their
data yielded similar results (between 0.5 and 0.3). However, the capture-recapture method has
multiple difficult-to-meet assumptions: closed population, statistical independence between
sources, identical case definitions across multiple sources and requires more personnel
resources [7,42]. Our study was less resource-intensive and provided an alternative to the cap-
ture-recapture method.
When screening strategies commonly used in community-based studies were explored, the
unadjusted prevalence was lower than the adjusted prevalence in the two most frequently
encountered scenarios, and the bias estimates were similar to that observed under the screen-
ing strategy used in the main analysis of this study. In our study, we had resources to capture
those missed through the first medical round and we screened for two neurological outcomes,
which resulted in more individuals being confirmed in step two compared to most commu-
nity-based studies. Despite this more complete examination of individuals screened positive,
the level of bias was similar to that estimated for screening strategies commonly used in com-
munity-based studies. In the last scenario explored, the prevalence relied entirely on the
screening questionnaire, which led to a large number of false positive cases of epilepsy. This
was especially true because the prevalence of epilepsy was relatively low, and hence, there were
relatively more people without epilepsy who were false positives than people with epilepsy who
were false negatives, even if the screening test’s specificity was much better than its sensitivity.
As opposed to the other scenarios, failure to use physician confirmation led to an overestimate
of the adjusted prevalence of epilepsy. This scenario could occur when economical and person-
nel resources are too limited for physician confirmation. For WSCH, the estimated negative
bias (i.e. when the unadjusted estimate was lower than the adjusted estimate) was more
marked in the two scenarios most often encountered in community-based studies than when
using the screening strategy in the main analysis of this study. This suggested that by only
screening for WSCH with or without two rounds, more WSCH cases were missed. There is ris-
ing evidence that seizures might increase the risk of headaches [48,49]. Hence, it is possible
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that screening for both outcomes improved the detection of WSCH through the neurological
examination of people screening positive for epilepsy. The opposite (i.e. the screening of peo-
ple with WSCH increases the detection of epilepsy) might not be as marked in our study
because a lot less participants screened positive for WSCH than for epilepsy or both epilepsy
and WSCH. In the last scenario where the prevalence estimate relied solely on the screening
questionnaire, we observed negligible positive bias for WSCH. This finding illustrated that
screening for both epilepsy and WSCH led to a less biased estimate of the prevalence compared
to the more commonly used approach of only screening for one neurological condition. This
was not observed for the last scenario for epilepsy because screening for WSCH along with epi-
lepsy might not increase the detection of epilepsy.
When we examined the impact of verification and misclassification bias on the estimation
of the prevalence and frequency of NCC-associated epilepsy and WSCH, we found that the
prevalence and number of NCC were underestimated when using two-step approach regard-
less of the scenario. In the scenario without confirmation by a physician or neurologist, we
found that the number of NCC-associated epilepsy cases were over-estimated, while we did
not observe a difference between the unadjusted and adjusted prevalence and number of
NCC-associated WSCH cases. These results could have important consequences in the estima-
tion of the monetary and non-monetary burden of NCC locally and globally. For example, the
estimated global DALYs of NCC-associated epilepsy were estimated to be 2,788,426 (95%
Uncertainty Estimates (UI): 2,137,613–3,606,582) by the Foodborne Epidemiology Research
Group in 2010 [50] and to be 468,100 (95% UI: 322,900–625,800) in 2016 by the Global Bur-
den of Disease 2016 Collaborative [51]. Moreover, the 2015 DALYs for migraine were esti-
mated to be 32,899,000 (95%UI: 20,295,000–48,945,000) [52]. If these estimates used
underlying NCC-associated epilepsy and headaches frequencies which were underestimated to
a similar level as in our study, it could have important consequences on how NCC would rank
among all diseases locally and globally and on policy making. Indeed, if the burden of NCC
were higher than currently believed, more resources should be allocated to control it.
Our study has several limitations. First, the physicians examined a small proportion of indi-
viduals screened negative. Increasing this proportion would have reduced the variance of our
posterior sensitivity estimates. Second, our study used two medical rounds with different phy-
sicians. However, perfect agreement between the two physicians was observed and all diagno-
ses were reviewed and confirmed by the neurologist, minimizing the possibility for bias.
Third, we could not conclude that our prevalence estimates for the study population were
reflective of the prevalence for the villages due to the sampling scheme. Since the aim of our
study was to quantify the bias that rose from failure to account for misclassification error and
verification biases by comparing the unadjusted estimates to the adjusted estimates, we believe
our findings were still of importance.
Our results suggest that the burden of epilepsy and WSCH in low-resource settings might
be much higher than previously reported. Future studies should consider using the statistical
models presented here to account for the imperfect nature of screening questionnaires. Bias-
adjusted prevalence estimates of these two neurological disorders will improve our under-
standing of the burden of these conditions and help identify where cysticercosis may be pres-
ent. More valid prevalence estimates will allow for the development of targeted cysticercosis
control programs in those communities.
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